BIOTRONIK First Launches ICDs with Exclusive MRI AutoDetect Feature in Japan

Ilivia ICDs with BIOTRONIK’s Award-Winning MRI AutoDetect Function Now Available in World’s Largest MRI Market ahead of Wider Launch

TOKYO, Japan, September 5, 2016 – Patients in Japan are the world’s first to benefit from BIOTRONIK’s Ilivia implantable cardioverter defibrillators (ICDs), which not only feature the company’s ProMRI technology, but also its exclusive, award-winning MRI AutoDetect function for enhanced patient safety. Japan is the world’s largest MRI market with more MRI scanners per capita than any other country: approximately 47 registered machines per one million people.1

BIOTRONIK already offers the world’s largest choice of ProMRI cardiac devices, and the new MRI AutoDetect feature improves ICD patient safety. Once activated, the smart function automatically recognizes when the patient is in an MRI environment. It then switches itself to MRI mode, and switches back to normal functionality when MRI fields are no longer detected. This potentially life-saving feature substantially reduces the length of time that Ilivia patients are left without full ICD therapy—a crucial advantage given that a dangerous cardiac arrhythmia requiring defibrillation can occur at any time.

This is an improvement over the current situation, in which ICD patients undergoing MRIs visit their cardiologist who programs the device into MRI mode, temporarily reducing its functionality. Following the scan, the cardiologist must program the device back to a non-MRI mode. The length of time this takes can vary after the MRI scan is completed. But with MRI AutoDetect, this window is reduced to only the duration of the scan itself.

“It’s only recently that MRI conditional devices have become the gold standard in CIEDs. These devices have seen continuous improvements, with the latest being the MRI AutoDetect function in Ilivia ICDs,” commented Dr. Shigetaka Kanda Tokai University Hospital, Tokyo, Japan. “The new function reduces the length of time a device is in MRI mode which is particularly beneficial for ICD patients as device therapy is disabled during this time. Thus the feature can improve patient safety and potentially save lives.”
Jeffrey Annis, Managing Director BIOTRONIK Japan pointed out that the MRI AutoDetect innovation is celebrated in the cardiology community, having won the Cardiostim Innovation Award in the category “Best Practice Improvement” in June. “Patients and physicians in Japan are keenly aware of the benefits of MRI conditional devices, and there is no doubt they will welcome this enhancement to device functionality,” he added.

  1. OECD Health Statistics 2013: http://dx.doi.org/10.1787/888932917275.


At BIOTRONIK, patient well-being is our top priority and has been for 60 years. BIOTRONIK is a leading global medical technology company with products and services that save and improve the lives of millions suffering from heart and blood vessel diseases as well as chronic pain. Driven by a purpose to perfectly match technology with the human body, we are dedicated innovators who develop trusted cardiovascular, endovascular and neuromodulation solutions. BIOTRONIK is headquartered in Berlin, Germany, and is represented in over 100 countries.